Funding · 18 May 2026Cellogen TherapeuticsRs 20 croreDevelops cell and gene therapies for cancer
FundingHealthcare & Life Sciences
Cellogen raises Rs 20 crore from Kotak Alts
By Abha Lohia · Editor ·
SeedFounded 2021
- Cellogen develops CAR-T cell therapies for cancers using AI-driven platforms
- The company raised Rs 20 crore led by Kotak Alternate Asset Managers
- It targets lower treatment costs compared to global standards of $500,000
What happened
- Cellogen Therapeutics has raised Rs 20 crore in funding from investors.
- Kotak Alternate Asset Managers led the investment round via its fund.
- The company plans to use funds for clinical programs and manufacturing expansion.
- Cellogen is preparing for Phase I human clinical trials with CMC Vellore.
- The startup aims to advance its gene therapy pipeline significantly this year.
- Cellogen holds a patent for its proprietary CAR-T platform technology.
- The firm operates a GMP-compliant facility in Noida for manufacturing.
- Investors include existing backer Natco Pharma which holds a small stake.
Why it matters
- Cellogen targets a price point of $60,000 to $70,000 per treatment.
- This cost is significantly lower than global CAR-T therapies costing up to $700,000.
- The Indian biotech sector supports over 11,000 startups currently.
- Government schemes like Biopharma SHAKTI aid domestic biotech development efforts.
The business
- Cellogen develops cell and gene therapies for treating various cancers.
- It uses Chimeric Antigen Receptor T-cell (CAR-T) technology for treatments.
- The core platform focuses on bispecific dual-antigen CAR-T therapy designs.
- These therapies target two cancer markers to reduce patient relapse risks.
- Early-stage programs address beta thalassemia and sickle cell disease conditions.
- The company utilizes AI-driven platforms for designing new therapeutic agents.
- A GMP-compliant facility in Noida handles in-house vector manufacturing.
- Cellogen received a patent for its CAR-T platform technology recently.
The founders
DG
Dr. Gaurav Kharya
Co-Founder- Co-founded Cellogen Therapeutics in 2021.
- Leads the scientific direction of the company's research initiatives.
DT
Dr. Tanveer Ahmad
Co-Founder- Co-founded Cellogen Therapeutics in 2021.
- Works alongside Dr. Kharya on developing novel therapeutic solutions.
Who put in money
- Kotak Alternate Asset Managers lead — Invests via Kotak Life Sciences Fund I.
- Natco Pharma existing — Acquired a 5.38% stake for slightly over Rs 15 crore previously.
In numbers
Rs 20 croreFunding Amount · 2026
$60,000-$70,000Treatment Price Target
$500,000-$700,000Global CAR-T Cost
>11,000Indian Biotech Startups
What happens next
- Cellogen will advance CAR-T clinical programs immediately after funding.
- The company plans to expand its gene therapy pipeline offerings.
- Regulatory approval is sought for Phase I trials with CMC Vellore.
- Manufacturing and regulatory capabilities will be strengthened using new capital.
Earlier rounds
- Prior to 2026 · Previous Stake Sale · Slightly over Rs 15 crore · led by Natco Pharma
Up against
ImmunoACT
Words to know
- CAR-T
- Chimeric Antigen Receptor T-cell therapy uses modified immune cells to fight cancer.
- GMP
- Good Manufacturing Practice ensures products are consistently produced to quality standards.
- Lentiviral Vector
- A virus-based tool used to deliver genetic material into cells for therapy.
- Bispecific
- Therapies designed to bind to two different antigens simultaneously for better targeting.
The numbers around it
Healthcare & Life Sciences in May 2026: 7 rounds with a disclosed amount, $11.9 million in all; the biggest was Gabit (₹36.2 Cr ($3.7 Mn)). Every sector this year →
Other articles talking about it
Terms in this story
- Lead investor: A lead investor is the investor that sets the price and main terms of a funding round, does the deepest checks on the company and usually puts in the largest cheque. When a headline says a round was led by a fund, that fund was the first to commit and shaped the deal that others joined.
Read next
FundingAugust AI raises $12M for US expansionAugust AI offers an AI health assistant that answers medical questions through WhatsApp and a mobile appFundingVitusCare raises $3 million Series BVitusCare runs dialysis units inside partner hospitals, which keeps costs low, and has grown from 22 to over 60 centresLaunchKapiva gives away Dia Free Juice on World Diabetes DayKapiva is a Bengaluru-based Ayurveda wellness brand selling herbal juices and supplements, with a flagship juice aimed at people managing blood sugar
All startup news on 18 May 2026 →
Is this Cellogen Therapeutics? Get your “Featured on StopDown” badge →